Identification of immune-enhanced molecular subtype associated with BRCA1 mutations, immune checkpoints and clinical outcome in ovarian carcinoma.

J Cell Mol Med · 2020 · PMC7077593 · PMID 31995855

Europe PMC DOI

hedged sentence

0.0650

closest p · 1.3× alpha

0.0650

boldest claim

The sentences

marginally significantP = .065so close (0.05 < p ≤ 0.1)

On the basis of the analysis of prognostic differences (Figure 6 D), the differences in prognosis between 4 subtypes were marginally significant ( P = .065), and the prognosis of C4 subtype was markedly poorer than that of the other subtypes; as shown by further analysis, the prognosis of C3 subtype was clearly better than that of C4 subtype (Figure 6 E), which was consistent with the validation dataset. 3.8.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.